$COGT
Cogent Biosciences, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021055947 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $0.00 $312.0K $530.0K
YoY Change -100.0% -69.41% -83.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.021M $5.600M $2.800M
YoY Change -10.34% 105.88% -8.5%
% of Gross Profit
Research & Development $14.80M $5.003M $5.129M
YoY Change 195.78% -51.59% -51.69%
% of Gross Profit
Depreciation & Amortization $48.00K $120.0K $280.0K
YoY Change -60.0% -62.5% -15.15%
% of Gross Profit
Operating Expenses $19.82M $5.003M $5.129M
YoY Change 296.14% -51.59% -51.69%
Operating Profit -$19.82M -$57.20M -$7.403M
YoY Change -65.35% 375.23% -29.77%
Interest Expense $115.0K $20.00K $0.00
YoY Change 475.0% -33.33% -100.0%
% of Operating Profit
Other Income/Expense, Net $735.0K $7.216M $10.00K
YoY Change -89.81% 6285.84% -60.0%
Pretax Income -$19.08M -$49.98M -$7.390M
YoY Change -61.82% 319.3% -29.75%
Income Tax
% Of Pretax Income
Net Earnings -$19.08M -$49.98M -$7.393M
YoY Change -61.82% 319.21% -29.7%
Net Earnings / Revenue -16020.19% -1394.91%
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$478.9K -$5.074M -$949.9K
COMMON SHARES
Basic Shares Outstanding 39.85M
Diluted Shares Outstanding 39.85M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $202.9M $129.4M $21.30M
YoY Change 56.79% 181.92% -61.9%
Cash & Equivalents $204.1M $130.7M $22.60M
Short-Term Investments
Other Short-Term Assets $4.616M $4.000M $2.600M
YoY Change 15.4% 233.33% 116.67%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $207.5M $133.4M $23.90M
YoY Change 55.55% 178.04% -59.21%
LONG-TERM ASSETS
Property, Plant & Equipment $4.590M $5.200M $5.900M
YoY Change -11.73% 139.63% 124.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.291M $1.300M $1.300M
YoY Change 153.15% 53.48% 53.66%
Total Long-Term Assets $7.881M $6.500M $7.200M
YoY Change 21.25% -34.38% -32.77%
TOTAL ASSETS
Total Short-Term Assets $207.5M $133.4M $23.90M
Total Long-Term Assets $7.881M $6.500M $7.200M
Total Assets $215.4M $139.9M $31.10M
YoY Change 53.96% 141.69% -55.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.349M $600.0K $600.0K
YoY Change 624.83% -62.36% -63.86%
Accrued Expenses $9.075M $5.700M $6.700M
YoY Change 59.21% -18.57% 4.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.71M $20.10M $8.300M
YoY Change -16.87% -17.72% -65.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.438M $3.700M $3.500M
YoY Change -61.14% -22.92% -32.69%
Total Long-Term Liabilities $1.438M $3.700M $3.500M
YoY Change -61.14% -22.92% -32.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.71M $20.10M $8.300M
Total Long-Term Liabilities $1.438M $3.700M $3.500M
Total Liabilities $18.15M $23.80M $11.80M
YoY Change -23.75% -18.66% -60.07%
SHAREHOLDERS EQUITY
Retained Earnings -$246.1M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $197.2M -$22.17M $19.24M
YoY Change
Total Liabilities & Shareholders Equity $215.4M $139.9M $31.10M
YoY Change 53.96% 141.69% -55.13%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$19.08M -$49.98M -$7.393M
YoY Change -61.82% 319.21% -29.7%
Depreciation, Depletion And Amortization $48.00K $120.0K $280.0K
YoY Change -60.0% -62.5% -15.15%
Cash From Operating Activities -$14.11M -$10.26M -$8.330M
YoY Change 37.51% 0.49% -26.54%
INVESTING ACTIVITIES
Capital Expenditures -$1.163M $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $8.420M $0.00
YoY Change -100.0% 4110.0% -100.0%
Cash From Investing Activities -$1.163M $8.420M $0.00
YoY Change -113.81% 3727.27% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.00K 109.9M 70.00K
YoY Change -99.95% -30.0%
NET CHANGE
Cash From Operating Activities -14.11M -10.26M -8.330M
Cash From Investing Activities -1.163M 8.420M 0.000
Cash From Financing Activities 55.00K 109.9M 70.00K
Net Change In Cash -15.22M 108.1M -8.260M
YoY Change -114.08% -1181.88% 154.94%
FREE CASH FLOW
Cash From Operating Activities -$14.11M -$10.26M -$8.330M
Capital Expenditures -$1.163M $0.00
Free Cash Flow -$12.95M -$8.330M
YoY Change -26.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2020Q3 cogt Research And Development Expense Acquired In Progress
ResearchAndDevelopmentExpenseAcquiredInProgress
46910000
cogt Research And Development Expense Acquired In Progress
ResearchAndDevelopmentExpenseAcquiredInProgress
46910000
CY2020Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7463000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7470000
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
620000
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
239000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1847000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
239000
CY2020Q3 cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
509000
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-343000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
735000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19084000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39848943
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
234667000
CY2021Q1 cogt Issuance Of Common Stock Value To Settle Liability
IssuanceOfCommonStockValueToSettleLiability
2043000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
260000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11728000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
226763000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2590000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16549000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
212804000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
31000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19084000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3463000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
197238000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
31762000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
35000
CY2020Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
808000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
507000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6094000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
25702000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
870000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7393000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
19241000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
335000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
13000
CY2020Q3 us-gaap Dividends Common Stock
DividendsCommonStock
11450000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3512000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-49983000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-22174000
us-gaap Profit Loss
ProfitLoss
-47361000
us-gaap Profit Loss
ProfitLoss
-63470000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
79000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
703000
us-gaap Share Based Compensation
ShareBasedCompensation
7834000
us-gaap Share Based Compensation
ShareBasedCompensation
5151000
cogt Noncash Consideration Received From Customer
NoncashConsiderationReceivedFromCustomer
808000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
44812000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7470000
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-343000
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
509000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1894000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2769000
cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1366000
cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-239000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2036000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-427000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3617000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2544000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2268000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1596000
cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-1516000
cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-353000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1315000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37986000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26484000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1286000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
320000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
8100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1286000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8420000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
98907000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10670000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
435000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
31000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
48000
cogt Payment To Contingent Value Right Holders
PaymentToContingentValueRightHolders
85000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
110060000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39302000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
91996000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
243445000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38679000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
204143000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130675000
us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
25481000
us-gaap Stock Issued1
StockIssued1
2043000
us-gaap Net Income Loss
NetIncomeLoss
-47400000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#222222;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#222222;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, the valuation of the CVR liability and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</p>
CY2020Q3 us-gaap Share Price
SharePrice
8.80
CY2021Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2021Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2020Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2020Q3 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2054000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1443000
CY2021Q3 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2025000
CY2020Q4 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2191000
CY2021Q3 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
1335000
CY2020Q4 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
161000
CY2021Q3 cogt Accrued Professional And Consulting Services
AccruedProfessionalAndConsultingServices
1408000
CY2020Q4 cogt Accrued Professional And Consulting Services
AccruedProfessionalAndConsultingServices
671000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
225000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
313000
CY2021Q3 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7047000
CY2020Q4 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
4779000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 cogt Preferred Stock Including Temporary Equity Shares Authorized
PreferredStockIncludingTemporaryEquitySharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42390225
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3463000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3512000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7834000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5151000
cogt Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2023-04
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
the Company’s option to extend for an additional five-year term.
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
900000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
900000
us-gaap Operating Lease Cost
OperatingLeaseCost
1812000
us-gaap Variable Lease Cost
VariableLeaseCost
616000
us-gaap Sublease Income
SubleaseIncome
1848000
us-gaap Lease Cost
LeaseCost
580000
us-gaap Operating Lease Payments
OperatingLeasePayments
2428000
CY2021Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0950
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
816000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2497000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
841000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2253000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1438000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3691000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19084000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-49983000
us-gaap Net Income Loss
NetIncomeLoss
-47361000
us-gaap Net Income Loss
NetIncomeLoss
-63470000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19084000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49983000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47361000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63470000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39848943
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9850530
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37741526
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8392741
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.56
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33978788
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41499610
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2021Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2020Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0001564590-21-055947-index-headers.html Edgar Link pending
0001564590-21-055947-index.html Edgar Link pending
0001564590-21-055947.txt Edgar Link pending
0001564590-21-055947-xbrl.zip Edgar Link pending
cogt-10q_20210930.htm Edgar Link pending
cogt-10q_20210930_htm.xml Edgar Link completed
cogt-20210930.xsd Edgar Link pending
cogt-20210930_cal.xml Edgar Link unprocessable
cogt-20210930_def.xml Edgar Link unprocessable
cogt-20210930_lab.xml Edgar Link unprocessable
cogt-20210930_pre.xml Edgar Link unprocessable
cogt-ex311_9.htm Edgar Link pending
cogt-ex312_8.htm Edgar Link pending
cogt-ex321_7.htm Edgar Link pending
cogt-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending